Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

Date: March 28, 2019
Pages: 297
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P06BDC863ABEN
Leaflet:

Download PDF Leaflet

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024
“Global plasma fractionation market is projected to grow at a CAGR of 6.6%.”

The global plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Growth in the plasma fractionation market can largely be attributed to factors such as the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

“By product, immunoglobulin market is expected to hold the largest share of the plasma fractionation market in 2019.”

The immunoglobulin segment is expected to dominate the plasma fractionation market during the forecast period. IVIg is the most extensively used plasma product across the globe, meant for the treatment of dermatomyositis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), immune cytopenias, hypogammaglobinemia, primary antibody deficiency, vacuities, multiple sclerosis, asthma, and systemic lupus erythematosus, among other ailments. The growing prevalence of these and other target diseases, as a result, is the key driver of market growth.

“Factor VIII will dominate the coagulation factor concentrates market in 2019.”

The coagulation factor market is segmented into factor VIII, factor IX, Von Willebrand factor, prothrombin factor concentrates, fibrinogen concentrates, and factor XIII. Factor VIII segment is expected to hold the largest share in the coagulation factor concentrates market in 2019. This is attributed to the growth in geriatric population, rising number of hemophilic patients, increasing preference for prophylactic treatments for people suffering from hemophilia, and increasing diagnosis of hemophilia. In addition, the unavailability of advanced therapies for a majority of hemophilia patients in developing countries is also expected to drive this market.

“North America is expected to hold the largest share during the forecast period (2019–2024)”

North America is expected to dominate the plasma fractionation market during the forecast period. The demand for plasma products in North America is mainly driven by the increasing use of immunoglobulins in neurological and autoimmune diseases and the increasing use of prophylaxis treatments among diagnosed patients. The rising number of registered hemophilic patients (as illustrated in the table below) is also propelling the growth of this market. The growing number of hemophilic patients will increase the adoption of coagulation factors, which in turn will drive the market for plasma fractionation in North America.

A breakdown of supply-side primary participants is mentioned below:
  • By Company Type: Tier 1–38%, Tier 2–21%, and Tier 3–41%
  • By Designation: C-level–30%, Director Level–28%, Others–42%
  • By Region: North America–35%, Europe–25%, Asia Pacific–20%, Latin America–12%, Middle East and Africa-8%
Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).

Research Coverage:

The plasma fractionation market in this report is segmented by product, application, end user, and region. It provides detailed information regarding the major factors influencing the growth market (drivers, restraints, opportunities, and industry-specific challenges). The study tracks and analyzes competitive developments (such as partnerships, agreements, collaborations, mergers & acquisitions, product developments, geographical expansions, and R&D activities) and strategically profiles the key players and comprehensively analyzes their market shares and core competencies in the plasma fractionation market.

Reasons to buy this report:

From an insight perspective, this research report has focused on various levels of analysis—the market share analysis of top players in the global market, different product segments, as well on the regional levels, company profiles that comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the plasma fractionation market; high-growth regions; and market drivers, restraints, and opportunities. The report provides the latest statistics and industry trends, allowing buyers to identify high-growth product segments and potential customers and suppliers, hence driving revenue growth and profitability. The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on products offered by the top players in the global plasma fractionation market
  • Product Development/Innovation: Detailed insights on growth strategies, research & development activities, and product launches in the global plasma fractionation market
  • Market Development: Comprehensive information about lucrative emerging markets–the report analyzes the markets for plasma fractionation across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global plasma fractionation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global plasma fractionation market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 SCOPE OF THE STUDY
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH APPROACH
  2.1.1 SECONDARY SOURCES
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY SOURCES
    2.1.2.1 Primary sources
    2.1.2.2 Key data from primary sources
    2.1.2.3 Key industry insights
2.2 MARKET SIZE ESTIMATION
  2.2.1 BOTTOM-UP APPROACH
  2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PLASMA FRACTIONATION MARKET OVERVIEW
4.2 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET
4.3 PLASMA FRACTIONATION MARKET: REGIONAL MIX
4.4 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS. DEVELOPED COUNTRIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 MARKET DRIVERS
    5.2.1.1 Growing use of immunoglobulins in various therapeutic areas
    5.2.1.2 Rising geriatric population across the globe
    5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin
    5.2.1.4 Increase in plasma collection
  5.2.2 MARKET RESTRAINTS
    5.2.2.1 High cost and limited reimbursement
    5.2.2.2 Emergence of recombinant alternatives
  5.2.3 MARKET OPPORTUNITIES
    5.2.3.1 Rising prevalence of bleeding disorders
  5.2.4 MARKET CHALLENGES
    5.2.4.1 Stringent government regulations

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION
6.2 KEY INDUSTRY TRENDS
  6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES
  6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS
  6.2.3 RISING ADOPTION OF SCIG
  6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS
  6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA
  6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS
6.3 PORTER’S FIVE FORCES
  6.3.1 THREAT OF NEW ENTRANTS
  6.3.2 THREAT OF SUBSTITUTES
  6.3.3 BARGAINING POWER OF SUPPLIERS
  6.3.4 BARGAINING POWER OF BUYERS
  6.3.5 INTENSITY OF COMPETITIVE RIVALRY
6.4 VENDOR BENCHMARKING
  6.4.1 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET
  6.4.2 NO. OF PLASMA COLLECTION CENTERS AND FRACTIONATION CAPACITIES, BY KEY PLAYER
  6.4.3 BUSINESS PRESENCE OF KEY PLAYERS IN THE VALUE CHAIN
6.5 PRICING ANALYSIS

7 PLASMA FRACTIONATION MARKET, BY PRODUCT

7.1 INTRODUCTION
7.2 IMMUNOGLOBULINS
  7.2.1 INTRAVENOUS IMMUNOGLOBULINS
    7.2.1.1 IVIg holds the largest share of the immunoglobulins market
  7.2.2 SUBCUTANEOUS IMMUNOGLOBULINS
    7.2.2.1 Benefit of self-administration and lower incidence of non-serious systemic adverse reactions will drive the growth of the SCIg market
  7.2.3 OTHER IMMUNOGLOBULINS
7.3 COAGULATION FACTOR CONCENTRATES
  7.3.1 FACTOR VIII
    7.3.1.1 Factor VIII holds the largest share of the coagulation factor concentrates market
  7.3.2 FACTOR IX
    7.3.2.1 Growth in the aging population and the rise in the number of hemophilic patients is expected to drive the growth in this market
  7.3.3 VON WILLEBRAND FACTOR
    7.3.3.1 Market growth is primarily driven by the increasing prevalence and diagnosis of Von Willebrand disease and hemophilia
  7.3.4 PROTHROMBIN COMPLEX CONCENTRATE
    7.3.4.1 Advantages of PCC over fresh frozen plasma will support market growth in this segment
  7.3.5 FIBRINOGEN CONCENTRATES
    7.3.5.1 Safety profile, accuracy, and speed of administration have supported the growth of the fibrinogen concentrates market
  7.3.6 FACTOR XIII
    7.3.6.1 Applications in treating rare bleeding disorders will contribute to the demand for Factor XIII
7.4 ALBUMIN
  7.4.1 WIDE DEMAND FOR ALBUMIN AS AN ANTIOXIDANT AND VOLUME EXPANDER WILL DRIVER MARKET GROWTH
7.5 PROTEASE INHIBITORS
  7.5.1 INCREASING GLOBAL DISEASE BURDEN WILL DRIVE DEMAND FOR PROTEASE INHIBITORS
7.6 OTHER PRODUCTS

8 PLASMA FRACTIONATION MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 NEUROLOGY
  8.2.1 RISING PREVALENCE OF MAJOR AGE-RELATED NEUROLOGICAL DISORDERS TO DRIVE THIS MARKET
8.3 IMMUNOLOGY
  8.3.1 INCREASING PREVALENCE OF IMMUNODEFICIENCY DISORDERS AMONG CHILDREN AND ADULTS TO DRIVE THE GROWTH OF THIS MARKET
8.4 HEMATOLOGY
  8.4.1 GROWTH IN THE NUMBER OF HEMOPHILIA PATIENTS TO DRIVE THE DEMAND FOR COAGULATION FACTOR CONCENTRATES AND IMMUNOGLOBULINS
8.5 CRITICAL CARE
  8.5.1 INCREASING OFF-LABEL USE OF ALBUMIN AND RISING USE OF ANTICOAGULANTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED CRITICAL CARE PRODUCTS
8.6 PULMONOLOGY
  8.6.1 RISING PREVALENCE OF ALPHA-1 ANTITRYPSIN DEFICIENCY AND COPD TO DRIVE THE PLASMA FRACTIONATION MARKET FOR PULMONOLOGY
8.7 HEMATO-ONCOLOGY
  8.7.1 RISING NUMBER OF BLOOD CANCER PATIENTS TO DRIVE THE DEMAND FOR PLASMA-DERIVED PRODUCTS IN HEMATO-ONCOLOGY
8.8 RHEUMATOLOGY
  8.8.1 INCREASING PREVALENCE OF RHEUMATIC CONDITIONS TO DRIVE THE PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY
8.9 OTHER APPLICATIONS

9 PLASMA FRACTIONATION MARKET, BY END USER

9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
  9.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND GROWTH IN THE NUMBER OF HOSPITALS & CLINICS—KEY FACTORS DRIVING GROWTH
9.3 CLINICAL RESEARCH LABORATORIES
  9.3.1 INCREASING NUMBER OF CLINICAL STUDIES ON NEW THERAPEUTIC INDICATIONS FOR PLASMA-DERIVED PRODUCTS TO DRIVE THE MARKET FOR CLINICAL RESEARCH LABORATORIES
9.4 ACADEMIC INSTITUTES
  9.4.1 INCREASING BASIC MEDICAL RESEARCH ACTIVITIES AND GROWING DEMAND FOR NEW DRUG MOLECULES TO DRIVE THE DEMAND FOR PLASMA PRODUCTS IN ACADEMIC INSTITUTES

10 PLASMA FRACTIONATION MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 US
    10.2.1.1 The US dominates the global plasma fractionation market
  10.2.2 CANADA
    10.2.2.1 Canada is one of the world's highest per capita users of IVIg
10.3 EUROPE
  10.3.1 GERMANY
    10.3.1.1 Germany has the highest plasma fractionation capacity in Europe
  10.3.2 FRANCE
    10.3.2.1 High prevalence of bleeding disorders to drive the market for plasma fractionation in France
  10.3.3 ITALY
    10.3.3.1 Growth in the country’s geriatric population to drive the market for plasma fractionation
  10.3.4 SPAIN
    10.3.4.1 Growing demand for plasma products for the treatment of chronic diseases in the elderly is the key factor driving market growth
  10.3.5 UK
    10.3.5.1 Increasing incidence of hemophilia and the growing consumption of coagulation factors to drive market growth in the UK
  10.3.6 REST OF EUROPE
10.4 ASIA PACIFIC
  10.4.1 CHINA
    10.4.1.1 Significant growth in the incidence of diseases such as hypoalbuminemia, liver cancer, and hepatitis B are driving the growth of plasma-derived products market in China
  10.4.2 JAPAN
    10.4.2.1 The rising geriatric population is expected to increase the prevalence of neurological disorders and hematological diseases in Japan in the coming years
  10.4.3 AUSTRALIA
    10.4.3.1 High production of plasma products and the growing demand for plasma products for the treatment of chronic disease to drive market growth
  10.4.4 INDIA
    10.4.4.1 Growing healthcare awareness, availability of better diagnostic tools, and the rising geriatric population to drive market growth
  10.4.5 VIETNAM
    10.4.5.1 Growing pool of patients suffering from COPD, PID, and bleeding disorders to drive market growth
  10.4.6 INDONESIA
    10.4.6.1 Growing government initiatives to drive market growth
  10.4.7 MALAYSIA
    10.4.7.1 Growing healthcare awareness, increasing prevalence of bleeding disorders, and the rising geriatric population are the major factors driving market growth
  10.4.8 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
  10.5.1 IMPLEMENTATION OF GOVERNMENT INITIATIVES TO PROMOTE HEALTHCARE SERVICES, RISING GERIATRIC POPULATION, AND INCREASING INCIDENCE OF BLEEDING DISORDERS TO DRIVE MARKET GROWTH IN LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
  10.6.1 TURKEY
    10.6.1.1 Turkey dominated the plasma fractionation market in the Middle East and Africa
  10.6.2 SAUDI ARABIA
    10.6.2.1 Rising use of immunoglobulins in neurology and immunology and the strengthening of healthcare infrastructure to drive market growth
  10.6.3 EGYPT
    10.6.3.1 Growing research on plasma and plasma derivatives and the increasing adoption of plasma products to drive market growth
  10.6.4 UAE
    10.6.4.1 Increasing incidence of bleeding disorders and growing government initiatives for healthcare infrastructure development to drive market growth
  10.6.5 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
  11.2.1 MARKET SHARE ANALYSIS, BY PRODUCT,2018
    11.2.1.1 Immunoglobulin market, by key players
      11.2.1.1.1 IVIG market, by key players
    11.2.1.2 Coagulation factor market, by key players
      11.2.1.2.1 Factor VIII market, by key players
    11.2.1.3 Albumin market, by key players
  11.2.2 MARKET SHARE ANALYSIS, BY REGION,2018
    11.2.2.1 North America plasma fractionation market, by key players
      11.2.2.1.1 US plasma fractionation market, by key players
    11.2.2.2 Europe plasma fractionation market, by key players
11.3 COMPETITIVE LEADERSHIP MAPPING
  11.3.1 VISIONARY LEADERS
  11.3.2 INNOVATORS
  11.3.3 DYNAMIC DIFFERENTIATORS
  11.3.4 EMERGING COMPANIES
11.4 COMPETITIVE SCENARIO AND TRENDS
  11.4.1 PRODUCT LAUNCHES/APPROVALS
  11.4.2 EXPANSIONS
  11.4.3 ACQUISITIONS
  11.4.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

12.1 CSL
12.2 GRIFOLS
12.3 SHIRE
12.4 OCTAPHARMA
12.5 KEDRION
12.6 LFB
12.7 BIOTEST
12.8 SANQUIN
12.9 CHINA BIOLOGIC PRODUCTS
12.10 BIO PRODUCTS LABORATORY (BPL)
12.11 JAPAN BLOOD PRODUCTS ORGANIZATION
12.12 GC PHARMA (GREEN CROSS CORPORATION)
12.13 SHANGHAI RAAS BLOOD PRODUCTS

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATION
13.5 RELATED REPORT
13.6 AUTHOR DETAILS

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN
FIGURE 2 SUPPLY SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 DEMAND SIDE: BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
FIGURE 4 DATA TRIANGULATION METHODOLOGY
FIGURE 5 IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, FROM 2019 TO 2024
FIGURE 6 NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 7 PLASMA FRACTIONATION MARKET, BY END USER, 2019 VS. 2024 (USD MILLION)
FIGURE 8 GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2018
FIGURE 9 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH
FIGURE 10 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2018
FIGURE 11 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 12 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING
THE FORECAST PERIOD
FIGURE 13 GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030
FIGURE 14 SOURCE PLASMA COLLECTION IN THE US, 2004–2017
FIGURE 15 PLASMA COLLECTION CENTERS IN THE US AND EUROPE, 2007–2016
FIGURE 16 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE, 2012–2017
FIGURE 17 PLASMA FRACTIONATION MARKET IN CHINA VS. US, 2017–2024
FIGURE 18 PORTER’S FIVE FORCES ANALYSIS
FIGURE 19 IMMUNOGLOBULIN SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024
FIGURE 20 PREVALENCE OF BLEEDING DISORDERS, BY COUNTRY, 2017
FIGURE 21 MEAN PER CAPITA USAGE OF FACTOR VIII (2016 VS 2017)
FIGURE 22 MEAN PER CAPITA USAGE OF FACTOR IX (2016 VS 2017)
FIGURE 23 NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2019 TO 2024
FIGURE 24 NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016 VS. 2017
FIGURE 25 HOSPITALS & CLINICS TO REGISTER THE HIGHEST CAGR DURING
THE FORECAST PERIOD
FIGURE 26 NORTH AMERICA TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
FIGURE 27 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 28 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 29 PLASMA COLLECTION VOLUME IN THE US, 2004–2017
FIGURE 30 PLASMA COLLECTION CENTERS IN THE US, 2005–2017
FIGURE 31 EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 32 HEMOPHILIA A & B PATIENTS IN GERMANY, 2013–2016
FIGURE 33 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT
FIGURE 34 FRESH BLOOD EXPENDITURE IN AUSTRALIA, 2008–2017 (USD MILLION)
FIGURE 35 MEAN PER CAPITA USE OF FACTOR VIII AND IX IN VIETNAM, 2014–2017 (IU/POPULATION)
FIGURE 36 PATIENT POPULATION SUFFERING FROM BLEEDING DISORDERS IN VIETNAM, 2014–2017
FIGURE 37 BLOOD DONATION IN INDONESIA, 2011–2015 (MILLION UNITS)
FIGURE 38 KEY STRATEGIES ADOPTED BY PLAYERS (JANUARY 2016 TO APRIL 2019)
FIGURE 39 PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 40 COMPETITIVE LEADERSHIP MAPPING
FIGURE 41 CSL: COMPANY SNAPSHOT (2018)
FIGURE 42 GRIFOLS: COMPANY SNAPSHOT (2017)
FIGURE 43 SHIRE: COMPANY SNAPSHOT (2017)
FIGURE 44 OCTAPHARMA: COMPANY SNAPSHOT (2018)
FIGURE 45 KEDRION: COMPANY SNAPSHOT (2017)
FIGURE 46 LFB: COMPANY SNAPSHOT (2016)
FIGURE 47 BIOTEST: COMPANY SNAPSHOT (2017)
FIGURE 48 SANQUIN: COMPANY SNAPSHOT (2017)
FIGURE 49 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2017)
FIGURE 50 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016)
FIGURE 51 GC PHARMA: COMPANY SNAPSHOT (2017)

Plasma-derived products, obtained from plasma fractionation, include albumin, immunoglobulins, coagulation factor concentrates, and others. These products are used in various clinical specialties settings, such as neurology, hematology, immunology, and nephrology.

This research study involved the use of widespread secondary sources; directories; databases such as Hoovers, Bloomberg, Businessweek, Factiva, and OneSource; white papers; annual reports; company house documents; and SEC filings. Secondary research was used to identify and collect information for an extensive, technical, market-oriented, and commercial study of this global market. It was also used to obtain important information about top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

In the primary research process, various sources from both supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply-side include industry experts such as CEOs, vice-presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the plasma fractionation market. Primary sources from the demand-side include industry experts such as plasma products providers and owners of plasma fractionation facilities.

Primary research was conducted to identify segmentation types; industry trends; Porter’s analysis; key players; competitive landscape of plasma products supplied by market players; and key market dynamics such as drivers, restraints, opportunities, burning issues, industry trends, and key player strategies.

The material was prepared in February, 2015.

LIST OF TABLES

TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS
TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG
TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017
TABLE 4 NUMBER OF PATIENTS TREATED FOR TOP 10 TARGET CONDITIONS IN
THE UK (2015-16)
TABLE 5 INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE
TABLE 6 NUMBER OF PLASMA COLLECTION CENTERS, BY COMPANY, 2018
TABLE 7 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING COUNTRIES, 2016 VS. 2017
TABLE 8 INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS
TABLE 9 FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYERS
TABLE 10 PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014)
TABLE 11 CHINA: TOP PLAYERS IN THE PLASMA FRACTIONATION MARKET, 2018
TABLE 12 MAJOR LOCAL PLAYERS IN CHINA
TABLE 13 REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON
PLASMA-DERIVED PRODUCTS
TABLE 14 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY PLAYER (2018)
TABLE 15 AVERAGE SELLING PRICE OF PLASMA FRACTIONATION PRODUCTS, BY REGION (2018)
TABLE 16 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 17 IVIG VS. SCIG THERAPY
TABLE 18 IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 19 IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20 INTRAVENOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 21 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22 INTRAVENOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (METRIC TONS)
TABLE 23 SUBCUTANEOUS IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 24 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25 SUBCUTANEOUS IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (METRIC TONS)
TABLE 26 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS
TABLE 27 OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28 OTHER IMMUNOGLOBULINS MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS)
TABLE 29 COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 30 COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 31 FACTOR VIII OFFERED BY KEY MARKET PLAYERS
TABLE 32 FACTOR VIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 33 FACTOR VIII MARKET, BY REGION, 2017–2024 (MILLION INTERNATIONAL UNITS)
TABLE 34 FACTOR IX OFFERED BY KEY MARKET PLAYERS
TABLE 35 FACTOR IX MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS
TABLE 37 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 38 PROTHROMBIN COMPLEX CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 39 PROTHROMBIN COMPLEX CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS
TABLE 41 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 42 FACTOR XIII OFFERED BY KEY MARKET PLAYERS
TABLE 43 FACTOR XIII MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 44 ALBUMIN OFFERED BY KEY MARKET PLAYERS
TABLE 45 ALBUMIN MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 46 GLOBAL ALBUMIN MARKET, BY REGION, 2017–2024 (METRIC TONS)
TABLE 47 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS
TABLE 48 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 49 OTHER PRODUCTS MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 51 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND THE PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030
TABLE 52 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN NEUROLOGY
TABLE 53 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54 LIST OF FDA-APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY
TABLE 55 PRIMARY IMMUNODEFICIENCY DISEASE, BY TYPE
TABLE 56 PREVALENCE OF PRIMARY IMMUNODEFICIENCY DISEASE, BY REGION, 2013 VS. 2015
TABLE 57 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN IMMUNOLOGY
TABLE 58 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 59 NUMBER OF HEMOPHILIA PATIENTS (2012–2017)
TABLE 60 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATOLOGY
TABLE 61 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 62 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN CRITICAL CARE
TABLE 63 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 64 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN PULMONOLOGY
TABLE 65 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 66 INCIDENCE OF LEUKEMIA, MULTIPLE MYELOMA, AND HODGKIN LYMPHOMA, BY REGION, 2012 VS. 2015 VS. 2018
TABLE 67 PLASMA-DERIVED PRODUCTS AND THEIR APPLICATIONS IN HEMATO-ONCOLOGY
TABLE 68 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 70 PLASMA-DERIVED PRODUCTS FOR OTHER APPLICATIONS
TABLE 71 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 72 PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 73 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 74 CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017)
TABLE 75 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 76 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 77 REGIONAL DISTRIBUTION OF PLASMA FRACTIONATION PLANTS AND PLASMA THROUGHPUT, BY REGION, 2014
TABLE 78 PLASMA FRACTIONATION MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 79 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2017
TABLE 80 TRANSFER OF PLASMA FROM US TO OTHER REGIONS, 2014
TABLE 81 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 83 NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 84 NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 85 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 86 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 87 US: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 88 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 89 US: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 90 US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 91 US: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 92 US: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 93 CANADA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 94 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 95 CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 96 CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 97 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 98 CANADA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 99 EUROPE: PLASMA COLLECTION, 2007–2016
TABLE 100 PLASMA FRACTIONATION PLANTS IN EUROPE (2017)
TABLE 101 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 102 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 103 EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 104 EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 105 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 106 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 107 GERMANY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 108 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 109 GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 110 GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 111 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 112 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 113 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE, 2012–2017
TABLE 114 FRANCE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 115 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 116 FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 117 FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 118 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 119 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 120 ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013
TABLE 121 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013, 2018-E, & 2023-E)
TABLE 122 ITALY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 123 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 124 ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 125 ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 126 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 127 ITALY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 128 SPAIN: KEY MACROINDICATORS FOR THE PLASMS FRACTIONATION MARKET
TABLE 129 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 130 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 131 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 132 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 133 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 134 USAGE OF IMMUNOGLOBULINS
TABLE 135 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS
IN THE UK, 2012–2016
TABLE 136 VOLUME OF IMMUNOGLOBULINS USED FOR THE TOP 5 DIAGNOSES (2016)
TABLE 137 UK: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 138 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 139 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 140 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 141 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 142 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 143 TOTAL NUMBER OF HEMOPHILIA PATIENTS IN REST OF EUROPE: 2012–2017
TABLE 144 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 145 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 146 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 147 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 148 ROE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 149 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 150 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 151 ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 152 ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 153 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 154 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 155 CHINA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 156 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 157 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 158 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 159 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 160 CHINA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 161 MEAN PER CAPITA FACTOR VIII AND IX USE IN JAPAN, 2014 VS. 2017
(IN IU/TOTAL POPULATION)
TABLE 162 PATIENTS WITH BLEEDING DISORDERS IN JAPAN, 2014 VS. 2017
TABLE 163 JAPAN: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 164 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 165 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 166 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 167 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 168 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 169 TOTAL IG (GRAMS) USED IN AUSTRALIA, 2006–2015
TABLE 170 AUSTRALIAN GOVERNMENT FUNDING FOR THE SUPPLY OF BLOOD AND BLOOD PRODUCTS, 2008–2017 (USD MILLION)
TABLE 171 AUSTRALIA: BLOOD SECTOR OVERVIEW (2017)
TABLE 172 AUSTRALIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 173 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 174 AUSTRALIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 175 AUSTRALIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 176 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 177 AUSTRALIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 178 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2016
TABLE 179 INDIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 180 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 181 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 182 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 183 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 184 INDIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 185 VIETNAM: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 186 VIETNAM: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 187 VIETNAM: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 188 VIETNAM: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 189 VIETNAM: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 190 VIETNAM: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 191 INDONESIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 192 INDONESIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 193 INDONESIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 194 INDONESIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 195 INDONESIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 196 INDONESIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 197 MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS, 2012–2017
TABLE 198 MALAYSIA: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 199 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 200 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 201 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 202 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 203 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 204 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 205 REST OF ASIA PACIFIC: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 206 REST OF ASIA PACIFIC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 207 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 208 REST OF ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 209 BRAZIL: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 210 MEXICO: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 211 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 212 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 213 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 214 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 215 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 216 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA, 2012–2017
TABLE 217 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION) IN SOUTH AFRICA, SAUDI ARABIA, AND IRAQ, 2012–2017
TABLE 218 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 219 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 220 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 222 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 224 TURKEY: DEMOGRAPHIC INDICATORS
TABLE 225 TURKEY: REPORTED CASES OF BLOOD DISORDERS, 2012 VS. 2014
TABLE 226 TURKEY: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 227 TURKEY: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 228 TURKEY: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 229 TURKEY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 230 TURKEY: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 231 TURKEY: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 232 ESTIMATED INCIDENCE AND PREVALENCE OF CID, SCID, AND MHC II DEFICIENCY IN CHILDREN IN SAUDI ARABIA
TABLE 233 PER CAPITA CONSUMPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND ALBUMIN (2015/2016)
TABLE 234 SAUDI ARABIA: BLOOD DISORDER CASES, BY TYPE, 2014 VS. 2016
TABLE 235 SAUDI ARABIA: KEY MACROINDICATORS FOR THE PLASMA
FRACTIONATION MARKET
TABLE 236 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 237 SAUDI ARABIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 238 SAUDI ARABIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 239 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 240 SAUDI ARABIA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 241 EGYPT: BLOOD DISORDER CASES, BY TYPE, 2014–2017
TABLE 242 EGYPT: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 243 EGYPT: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 244 EGYPT: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 245 EGYPT: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 246 EGYPT: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 247 EGYPT: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 248 UAE: GROWTH IN THE NUMBER OF BLOOD DONORS
TABLE 249 UAE: KEY MACROINDICATORS FOR THE PLASMA FRACTIONATION MARKET
TABLE 250 UAE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 251 UAE: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 252 UAE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 253 UAE: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 254 UAE: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 255 HEMOPHILIA PATIENTS IN THE REST OF MIDDLE EAST AND AFRICA, 2012 VS. 2017
TABLE 256 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII IN SOUTH AFRICA AND QATAR (IU/TOTAL POPULATION), 2013 VS. 2017
TABLE 257 ROMEA: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2017–2024 (USD MILLION)
TABLE 258 ROMEA: IMMUNOGLOBULINS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 259 ROMEA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 260 ROMEA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 261 ROMEA: PLASMA FRACTIONATION MARKET, BY END USER, 2017–2024 (USD MILLION)
TABLE 262 GROWTH STRATEGY MATRIX
TABLE 263 PRODUCT LAUNCHES/APPROVALS, JANUARY 2016 TO APRIL 2019
TABLE 264 EXPANSIONS, JANUARY 2016 TO APRIL 2019
TABLE 265 ACQUISITIONS, JANUARY 2016 TO APRIL 2019
TABLE 266 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2016 TO APRIL 2019

Skip to top


Ask Your Question

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: